Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
Purpose: This study will collect information about markers of inflammation, blood clotting and blood vessel function in HIV-infected adults and healthy volunteers. Certain markers of inflammation, blood clotting, and blood vessel function have been associated with risk of cardiovascular disease, stroke and death. This study will further explore D-dimer and other biomarkers to try to better understand the relationships between them and HIV infection. This study is currently recruiting participants. Healthy volunteers and HIV-infected adults 18 years of age or older may be eligible for this study.
Contact: Patient Recruitment and Public Liaison Office at 800-411-1222 or firstname.lastname@example.org
ClinicalTrials.gov Identifier: NCT00776412
Genetic Susceptibility to Factor VIII Inhibitors
Purpose: This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII. Bleeding episodes in patients with inhibitors are often more difficult to treat. Previous research indicates that genetic factors play a role in the development of inhibitors. A better understanding of the influence of genes in this treatment complication may be helpful in predicting, treating or preventing inhibitors. This study is currently recruiting participants. People in families in which one or more members have severe factor VIII deficiency and one or more have a history of an inhibitor may be eligible for this study.
Contact: Cheryl Winkler, PhD at 301-846-5747 or email@example.com
ClinicalTrials.gov Identifier: NCT00344435
Personalized Warfarin Dosing by Genomics and Computational Intelligence
Purpose: This study will create a computer program that can be used to help dose warfarin for the prevention of blood clotting. The study will collect specific information about those patients receiving this drug and use that information to create a computer program that will predict the effects of the drug. With this prediction program in place study, investigators can perform a series of “what if I gave this amount of drug” simulations to determine the best dose of drug for that patient. Once the computer programs are developed, the investigators will test the program in patients needing the medication. The investigators will also include genetic information into the prediction, since it has been shown that this information can affect how well the drug works. Patients will have this genetic information determined during this study. This study is currently recruiting participants.
Contact: Melissa Jordan, BA at 502-852-2290.
ClinicalTrials.gov Identifier: NCT00872079